Synonym
Nitraquazone; Nitraquazona; Nitraquazonum
IUPAC/Chemical Name
3-Ethyl-1-(m-nitrophenyl)-2,4(1H,3H)-quinazolinedione
InChi Key
GNWCRBFQZDJFTI-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H13N3O4/c1-2-17-15(20)13-8-3-4-9-14(13)18(16(17)21)11-6-5-7-12(10-11)19(22)23/h3-10H,2H2,1H3
SMILES Code
O=C(N1CC)N(C2=CC=CC([N+]([O-])=O)=C2)C3=C(C=CC=C3)C1=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
311.29
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Souness JE, Rao S. Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal. 1997 May-Jun;9(3-4):227-36. doi: 10.1016/s0898-6568(96)00173-8. PMID: 9218122.
2: Dal Piaz V, Giovannoni MP. Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies. Eur J Med Chem. 2000 May;35(5):463-80. doi: 10.1016/s0223-5234(00)00179-3. PMID: 10889326.
3: Kelly JJ, Barnes PJ, Giembycz MA. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors. Br J Pharmacol. 1998 May;124(1):129-40. doi: 10.1038/sj.bjp.0701819. PMID: 9630352; PMCID: PMC1565372.
4: Palacios JM, Beleta J, Segarra V. Second messenger systems as targets for new therapeutic agents: focus on selective phosphodiesterase inhibitors. Farmaco. 1995 Dec;50(12):819-27. PMID: 8634072.
5: Kelly JJ, Barnes PJ, Giembycz MA. Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(-)-rolipram binding by selective inhibitors. Biochem J. 1996 Sep 1;318 ( Pt 2)(Pt 2):425-36. doi: 10.1042/bj3180425. PMID: 8809029; PMCID: PMC1217639.
6: Van Wauwe J, Aerts F, Walter H, de Boer M. Cytokine production by phytohemagglutinin-stimulated human blood cells: effects of corticosteroids, T cell immunosuppressants and phosphodiesterase IV inhibitors. Inflamm Res. 1995 Sep;44(9):400-5. doi: 10.1007/BF01797868. PMID: 8846199.
7: Chan SC, Hanifin JM. Differential inhibitor effects on cyclic adenosine monophosphate-phosphodiesterase isoforms in atopic and normal leukocytes. J Lab Clin Med. 1993 Jan;121(1):44-51. PMID: 8381148.
8: Alvarez R, Sette C, Yang D, Eglen RM, Wilhelm R, Shelton ER, Conti M. Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. Mol Pharmacol. 1995 Oct;48(4):616-22. PMID: 7476886.
9: Molnar-Kimber K, Yonno L, Heaslip R, Weichman B. Modulation of TNF alpha and IL-1 beta from endotoxin-stimulated monocytes by selective PDE isozyme inhibitors. Agents Actions. 1993;39 Spec No:C77-9. doi: 10.1007/BF01972726. PMID: 8273592.
10: Spina D, Ferlenga P, Biasini I, Moriggi E, Marchini F, Semeraro C, Page CP. The effect duration of selective phosphodiesterase inhibitors in the guinea pig. Life Sci. 1998;62(11):953-65. doi: 10.1016/s0024-3205(98)00015-0. PMID: 9515552.
